Foghorn

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

Retrieved on: 
Thursday, February 8, 2024

Selective BRM inhibition has been a sought-after objective in cancer research for many years.

Key Points: 
  • Selective BRM inhibition has been a sought-after objective in cancer research for many years.
  • A variety of tumor types, including NSCLC, are known to have mutations in BRG1, which we believe make them dependent on BRM activity for their survival.
  • Selective blocking of BRM activity is considered a promising strategy for causing tumor cell death while sparing healthy cells.
  • The collaboration includes a US 50/50 co-development and co-commercialization agreement for Foghorn’s Selective BRM oncology program and an additional undisclosed oncology target.

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Retrieved on: 
Friday, January 5, 2024

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.
  • A seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company.
  • “I am delighted to welcome Allan to Prime Medicine.
  • He brings tremendous financial, operational and leadership experience in the life sciences space, as well as a proven track record developing and implementing multi-pronged strategies to finance a diverse pipeline and broad platform,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Retrieved on: 
Thursday, November 2, 2023

“During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.

Key Points: 
  • “During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.
  • Foghorn commenced a Phase 1 study of FHD-286 in combination with decitabine or low-dose cytarabine (LDAC) in relapsed and/or refractory AML patients, with the first patient dosed during the third quarter of 2023.
  • As of September 30, 2023, the Company had $259.9 million in cash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026.
  • Net loss was $14.3 million for the three months ended September 30, 2023, compared to a net loss of $25.8 million for the three months ended September 30, 2022.

Foghorn Consulting and Carahsoft Announce Partnership to Deliver Comprehensive AWS Cloud Solutions to the Public Sector

Retrieved on: 
Wednesday, November 1, 2023

SAN FRANCISCO and RESTON, Va., Nov. 1, 2023 /PRNewswire-PRWeb/ -- Foghorn Consulting, a distinguished AWS cloud engineering firm, and Carahsoft Technology Corp., The Trusted Government IT Solutions Provider®, today announced a partnership tailored to address the unique cloud challenges of the Federal and State, Local and Education (SLED) sectors.

Key Points: 
  • With a history of successfully guiding clients through cloud transformations, Foghorn delivers customized solutions that foster innovation and operational efficiency within cloud architecture.
  • Carahsoft leverages its extensive experience in the industry, its reseller partnerships, Government contracts and status as an AWS managed service company to deliver advanced cloud solutions for the Public Sector.
  • Foghorn Consulting offers expertise in various aspects of public cloud engineering, including strategy, migration, design, implementation, and ongoing support via FogOps.
  • For more information about this partnership and the tailored AWS cloud solutions it offers to the SLED and Federal sectors, please visit Foghorn Consulting's website and Carahsoft's website .

Smart Building Awareness and Sustainability Drive Building Automation System Market to Grow 7.4% CAGR by 2033

Retrieved on: 
Wednesday, November 1, 2023

NEWARK, Del., Nov. 1, 2023 /PRNewswire/ -- Building Automation System Market Segmentation by HVAC and Lighting Solutions, with Growth Opportunities and Revenue Forecast 2023 -2033

Key Points: 
  • NEWARK, Del., Nov. 1, 2023 /PRNewswire/ -- Building Automation System Market Segmentation by HVAC and Lighting Solutions, with Growth Opportunities and Revenue Forecast 2023 -2033
    The building automation system market is expected to be US$ 47,800 million in 2023.
  • The market's progress is expected to be encouraging over the 2023 to 2033 period, with a CAGR of 7.4%.
  • Request a sample report to preview our comprehensive building automation system market research report before you purchase.
  • Building automation systems is a well-known way to achieve smart buildings, smart cities, and smart living.

Smart Building Awareness and Sustainability Drive Building Automation System Market to Grow 7.4% CAGR by 2033

Retrieved on: 
Wednesday, November 1, 2023

NEWARK, Del., Nov. 1, 2023 /PRNewswire/ -- Building Automation System Market Segmentation by HVAC and Lighting Solutions, with Growth Opportunities and Revenue Forecast 2023 -2033

Key Points: 
  • NEWARK, Del., Nov. 1, 2023 /PRNewswire/ -- Building Automation System Market Segmentation by HVAC and Lighting Solutions, with Growth Opportunities and Revenue Forecast 2023 -2033
    The building automation system market is expected to be US$ 47,800 million in 2023.
  • The market's progress is expected to be encouraging over the 2023 to 2033 period, with a CAGR of 7.4%.
  • Request a sample report to preview our comprehensive building automation system market research report before you purchase.
  • Building automation systems is a well-known way to achieve smart buildings, smart cities, and smart living.

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

Retrieved on: 
Tuesday, October 24, 2023

The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland.

Key Points: 
  • The TPD Summit will be held October 30–November 2 in Boston, Massachusetts, and CTOS will be held November 1–4 in Dublin, Ireland.
  • Foghorn will participate in multiple sessions, including a keynote presentation by Steve Bellon, Foghorn’s Chief Scientific Officer, where data from its selective EP300 and CBP degrader programs will be presented.
  • Danette Daniels, Foghorn’s Vice President, Protein Degradation Platform, will provide the conference’s opening remarks as the Chair.
  • Presenter: Laura La Bonte, Senior Director, Biology & Research Portfolio Strategy, Foghorn Therapeutics

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Retrieved on: 
Wednesday, October 4, 2023

The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Key Points: 
  • The conference will be held October 11–15, 2023, in Boston, Massachusetts.
  • Foghorn will highlight data from its FHD-286 program demonstrating its potential as a broad-based hematologic and solid tumor differentiation agent, including clinical data in acute myeloid leukemia (AML), metastatic uveal melanoma (mUM), and pre-clinical data in non-small cell lung cancer (NSCLC) and prostate cancer.
  • Also at AACR-NCI-EORTC, the Company will present data from its selective EP300 program, including in vitro selective degradation and antiproliferation in AR+ prostate and DLBCL cell lines.
  • The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.

IOTech Expands North American Presence with Investment from Dell Technologies Capital

Retrieved on: 
Tuesday, August 29, 2023

IOTech , the leader in open edge computing, today announced its expansion in the North American market, fueled by additional investment led by Dell Technologies Capital.

Key Points: 
  • IOTech , the leader in open edge computing, today announced its expansion in the North American market, fueled by additional investment led by Dell Technologies Capital.
  • The new investment included existing investors Dell Technologies Capital, SPDG (Société Anonyme de Participation et De Gestion), the holding company of the Périer-D’Ieteren family, Northstar Ventures and the Scottish Investment Bank.
  • Their technology has proven to be valuable to manufacturing and energy customers,” said Gregg Adkin, managing director with Dell Technologies Capital.
  • As part of its expansion across North America, IOTech recently expanded its technology expertise with the addition of field CTOs.

Foghorn Therapeutics Announces Chief Medical Officer Succession

Retrieved on: 
Tuesday, August 8, 2023

CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced that Alfonso Quintás-Cardama, M.D., will join the company as Chief Medical Officer, on September 11, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced that Alfonso Quintás-Cardama, M.D., will join the company as Chief Medical Officer, on September 11, 2023.
  • Foghorn’s current Chief Medical Officer, Sam Agresta, M.D., will simultaneously retire from the company on September 11, 2023, and will provide consulting services through early January 2024.
  • “I want to thank Sam for his leadership and many contributions to Foghorn over the past four years.
  • He joined the company at a critical time and built our clinical team which advanced our first programs to the clinic,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.